Benzinga | Aug 5, 2020 04:15PM EDT

Atara Biotherapeutics Q2 EPS $(1.14) Beats $(1.18) Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.18) by 3.39 percent. This is a 28.75 percent increase over losses of $(1.60) per share from the same period last year.